Journal
VASCULAR PHARMACOLOGY
Volume 51, Issue 1, Pages 1-7Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.vph.2009.02.002
Keywords
Angiogenesis; Rheumatoid arthritis; Targeting; Angiogenic mediators; Angiostatic agents
Categories
Funding
- NIAID NIH HHS [R01 AI040987, AI-40987, R01 AI040987-08] Funding Source: Medline
- NIAMS NIH HHS [R01 AR048267, AR-048267, R01 AR048267-05] Funding Source: Medline
Ask authors/readers for more resources
Angiogenesis, the development of new capillaries, is involved in leukocyte ingress into the synovium during the development and progression of rheumatoid arthritis. Several soluble and cell surface-bound mediators including growth factors, cytokines, chemokines, proteolytic matrix-degrading enzymes, cell adhesion molecules and others may promote synovial neovascularization. On the other hand, endogenous angiostatic factors, such as angiostatin, endostatin, interleukin-4 (IL-4), IL-13, interferons and some angiostatic chemokines are also produced within the rheumatoid synovium, however, their effects are insufficient to control synovial angiogenesis and inflammation. Several specific and non-specific strategies have been developed to block the action of angiogenic mediators. The first line of angiostatic agents include vascular endothelial growth factor (VEGF), angiopoietin, alpha(v)beta(3) integrin antagonist, as well as non-specific angiogenesis inhibitors including traditional disease-modifying agents (DMARDs), anti-tumor necrosis factor biologics, angiostatin, endostatin, fumagillin analogues or thalidomide. Potentially any angiostatic compound Could be introduced to studies using animal models of arthritis or even to human rheumatoid arthritis trials. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available